PDE5A and pulmonary arterial hypertension: Consistent with these clinical guidelines, it will be important to assess the efficacy of NTP42 alongside other therapies such as PDE5 inhibitors (e.g. Sildenafil), prostacyclin analogues (e.g. Selexipag) or members of the ERA class of PAH treatments.